Silver Book Fact

Increased use of a blood-thinning drug saves $600 million annually, because of the strokes it prevents.

Secondary and Tertiary Prevention of Stroke Patient Outcomes Research Team Final Report — Phase 1. AHRQ Web site. http://www.ahrq.gov/clinic/strokcln.htm. Published June 2000

Reference

Title
Secondary and Tertiary Prevention of Stroke Patient Outcomes Research Team Final Report — Phase 1
Publication
AHRQ
Publication Date
Published June 2000
Authors
Matchar, David, and Gregory Samsa
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Economic Value

Related Facts

  • The projected economic value of eliminating deaths from heart disease is approximately $48 trillion.  
  • In 2005, approximately 469,000 coronary artery bypass procedures were performed on 261,000 patients in the U.S.  
  • Effectiveness of treating ischemic strokert-PA within 3 hours of symptom onset
    A study of the  victims with effectiveness of treating ischemic strokert-PA within 3 hours of symptom onset showed a decrease in rehabilitation costs of $1.4 million and nursing home costs of…  
  • TAVR v. SAVR in Intermediate-Risk SAS Patients
    At 1-year, severe aortic stenosis (SAS) patients with intermediate surgical mortality risk who underwent transcatheter aortic valve replacement (TAVR), had all-cause mortality rates of 7.4% (compared to 13% for surgical…  
  • Survival rates of SAS patients ages 80+ with and without SAVR